Recombinant Epidermal Growth Factor (EGF)

EGF, or Epidermal Growth Factor, is a naturally occurring mitogenic protein that stimulates cell growth, proliferation, and differentiation by binding to the EGF receptor (EGFR).

Immobazyme produces recombinant human EGF using microbial expression systems for high purity, consistent bioactivity, and animal-free formulations.

EGF is widely used in:

• Mammalian cell culture media supplementation

• Skin regeneration and wound healing studies

• Stem cell and epithelial cell research

• Cosmetic product development

Importantly, clinical studies have shown that EGF significantly promotes the healing of diabetic foot ulcers (DFUs) by accelerating cell proliferation, angiogenesis, and tissue regeneration. This makes it a promising candidate for regenerative medicine, chronic wound therapy, and bioactive dressing research.

Recommended concentrations of EGF range from 1 ng/mL to 50 ng/mL, depending on the cell type, serum conditions, and application goals.

Lower doses are typically used for maintenance, while higher concentrations may be required for wound healing or tissue regeneration models.

Our recombinant EGF is ≥95% pure, confirmed through SDS-PAGE. Each LOT is manufactured to be free from endotoxins, host cell proteins, and animal-derived components, ensuring reproducibility in sensitive biological systems.

Purity verification: SDS-PAGE and Coomassie staining

EGF (LOT: 20250123-EGF) run on an SDS-PAGE gel after lyophilisation. A prominent band representing EGF was present with ±90% purity.

Immobazyme’s EGF is validated for biological activity using MTT proliferation assays as well as standard strach assays.

Effect of EGF on HaCaT cell proliferation

Effect of EGF (20250123-EGF) on HaCaT keratinocyte cell proliferation, tested over 48 hours.

To reconstitute the lyophilised powder:

• Remove red safety cap from vial.

• Aspirate 1 mL of sterile milliQ water into a 1 mL sterile syringe.

• Attach a sterile needle onto the syringe and insert into the vial through the centre of the rubber stopper seal.

• Gently inject the 1 mL of water into the vial, then remove the needle and syringe.

• Invert the vial 5-10 times, or until the lyophilised sample is fully reconstituted.

• Insert the needle and syringe into the reconstituted sample vial, invert the vial and gently aspirate the sample liquid into the 1 mL syringe, being sure to collect the full volume by keeping the needle end near the rubber stopper opening.

• Inject the reconstituted 1 mL sample into a sterile microfuge tube through a 0.22 μm syringe filter (provided).

• Prepare stock concentrations in sterile microfuge tubes as per your relevant standard operating procedures, keeping in mind the avoidance of repeated freeze-thaw cycles.

• Prepare working concentration stocks in sterile microfuge tubes as per your relevant standard operating procedures. The recommended working concentration for EGF is 1-100 ng/mL.

Yes. Our recombinant human EGF is produced without any animal-derived components, making it fully compatible with xeno-free, serum-free, and chemically defined media.

It is ideal for use in clinical research, stem cell culture, and cosmetic-grade R&D.

EGF is widely used in cosmeceuticals for its ability to support skin regeneration, collagen production, and wound healing.

In cosmetic formulations, it is commonly referred to by its INCI name, sh- Oligopeptide-1. Immobazyme offers this product specifically for cosmetic R&D and formulation under our peptide line.

Yes. We offer evaluation samples of EGF for qualified research institutions, biotech companies, and cosmetic formulators.

Please contact our team to request a sample and share your intended use case.

• The lyophilised vial can be stored at –20 °C for 12 months.

• The reconstituted protein aliquots can be stored at –20°C for 6 months.

• Once resuspended use within 1 week (storage at 4°C).